Genes, Proteins, and Metabolites in Drug-resistant Epilepsy (DRE) Patients
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Routine clinical treatment.
- Who it may be relevant to
- Registry conditions: Drug Resistant Epilepsy, Traumatic Brain Injury Without Open Intracranial Wound. Basic parameters: 14 years — 60 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Changes of Genes, Proteins, and Metabolites in Patients with Drug-resistant Epilepsy
Overview
In patients with drug-resistant epilepsy (DRE), there may be changes at the genetic, proteomic, and metabolomic levels when comparing epileptic tissues from DRE to normal tissues in traumatic brain injury (TBI). These changes could help in understanding the pathophysiological mechanisms of epilepsy and in identifying new therapeutic targets.
Detailed description
Genomical studies have identified changes in the expression of certain genes within epileptic tissues. These genes may be involved in pathways related to the balance of neuronal excitability and inhibition, synaptic transmission, and cell apoptosis.
Proteomic studies will reveal changes in the abundance and modifications of proteins in epileptic tissues. These could involve proteins related to the control of neuronal excitability and synaptic transmission, such as ion channels, neurotransmitter receptors, and synaptic proteins.
Metabolomic researches will reveal changes in metabolites within epileptic tissues. Epilepsy may lead to disruptions in metabolic pathways, affecting key processes such as energy metabolism, amino acid metabolism, and lipid metabolism.
Sample Size: There is no minimum or maximum, but is expected to be far less than 10.
In summary, patients with drug-resistant epilepsy might have changes in genes, proteomics, and metabolomics within epileptic tissues compared to normal tissue from TBI. Further research into these changes will deepen our understanding of the pathophysiology of epilepsy and guide the need for new treatment strategies.
Interventions
- Other Routine clinical treatment
Routine clinical treatment is based on the latest international guidelines for DRE.
Primary outcome measures
- Single cell RNA sequencing [Time frame: through study completion, an average of one year]
Secondary outcome measures (2)
- Differentially expressed proteins [Time frame: through study completion, an average of one year]
- The concentration of metabolites [Time frame: through study completion, an average of one year]
Eligibility criteria
Inclusion criteria
- 14-60 years old, male or female, Han Chinese;
- Drug-resistant epilepsy;
- Required surgical implantation of SEEG electrodes.
Exclusion criteria
- Progressive encephalopathy or progressive structural damage in the central nervous system;
- Significant heart, liver, renal insufficiency, and other medical diseases;
- Severe side effects from taking antiepileptic drugs at the time of enrollment and not inappropriate for SEEG;
- Significant intellectual disability;
- A history of alcohol and drug abuse;
- Any contraindication to MRI.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Xuanwu Hospital, Capital Medical University — Beijing
Identifiers
NCT: NCT06665880 · Brain Tissues